GALANTAMINE ER CAPSULE (EXTENDED RELEASE)
Riik: Kanada
keel: inglise
Allikas: Health Canada
Toote omadused
(SPC)
23-06-2017
Mõned selle toote dokumendid pole praegu saadaval. Võite saata päringu meie klienditeenindusele ja me teavitame teid sellest niipea, kui meil on neid võimalik hankida.
Saada päring.
Saada päring.
Toimeaine:
GALANTAMINE (GALANTAMINE HYDROBROMIDE)
Saadav alates:
SANIS HEALTH INC
ATC kood:
N06DA04
INN (Rahvusvaheline Nimetus):
GALANTAMINE
Annus:
8MG
Ravimvorm:
CAPSULE (EXTENDED RELEASE)
Koostis:
GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8MG
Manustamisviis:
ORAL
Ühikuid pakis:
100
Retsepti tüüp:
Prescription
Terapeutiline ala:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Toote kokkuvõte:
Active ingredient group (AIG) number: 0144660002; AHFS:
Volitamisolek:
APPROVED
Loa andmise kuupäev:
2016-01-07
Toote omadused
Page 1 of 55
PRODUCT MONOGRAPH
PR
GALANTAMINE ER
Galantamine Hydrobromide Extended-Release Capsules
8 mg, 16 mg, 24 mg galantamine base
Cholinesterase Inhibitor
SANIS HEALTH INC.
1 President's Choice Circle
Brampton, Ontario
L6Y 5S5
Date of Revision: June 22, 2017
Submission Control No: 206599
Page 2 of 55
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
...............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND STABILITY
.........................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.........................................................................
25
CLINICAL TRIALS
.........................................................................................................
26
DETAILED PHARMACOLOGY
..............................................
Lugege kogu dokumenti
